Stock Groups

Moderna says its COVID-19 vaccine protective, safe in young children -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: Moderna coronavirus vaccine (COVID-19), prepared by medical staff for use at the recently-opened Tokyo mass vaccination center, Tokyo, Japan. This was May 24, 2021. Carl Court/Pool via REUTERS

(Reuters). Moderna Inc stated Monday that COVID-19 generated a strong immune reaction and was well tolerated by children six- to eleven years of age, citing interim results from a study.

According to the company’s statement, they plan to soon submit data to U.S., European, and other regulators.

Moderna (NASDAQ:) The data revealed that two doses of 50 micrograms of vaccine generated antibodies against the virus in children. This is half of what was used for adults.

According to company statements, side effects tend to be mild-to-moderate in severity. Fatigue, headaches, fever, and pain at the injection site were some of the most commonly reported adverse effects.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]